£350 million GlaxoSmithKline facility to create 200 jobs

Proposals for a new £350 million biopharmaceutical facility at GSK in Ulverston have been given the go ahead by South Lakeland District Council’s planning committee today.

The project, which would take place in three phases over the next 15 years, is expected to create 200 permanent jobs at the facility.

Construction during the initial phase will include a new production facility and an associated office and laboratory building.

The second and third phases, provisionally set for 2025 and 2030 respectively, would be built on the site of the existing GSK sports facilities.

In total, the completed project is expected to bring more than 700 jobs to Ulverston.

The planning report said: “The proposed Biopharmaceutical Manufacturing facility represents a major development for South Lakeland and will deliver significant economic benefits for the area in terms of high quality, highly skilled jobs, both at the construction and operational phases, opportunities for supply chain links with local companies, and the creation of educational and training links with local schools, colleges and Universities.

“It will also deliver a number of social and environmental benefits including the provision of new and improved sports facilities, biodiversity improvements and new and enhanced pedestrian and cycle routes.”